Bipolar II compared with bipolar I disorder: baseline characteristics and treatment response to quetiapine in a pooled analysis of five placebo-controlled clinical trials of acute bipolar depression

Table 4 Least squares MADRS score change (mean, SE) during treatment in bipolar I and II subgroups (ITT population)

Treatment	Bipolar I n = 1162			Bipolar II n = 598
Treatment	n	Least squares MADRS score change (mean, SE)	Probability^a	n	Least squares MADRS score change (mean, SE)	Probability^a
Quetiapine
Week 4	944	−15.01 (0.27)	<.01	484	−13.96 (0.38)	<.01
Week 8	781	−19.01 (0.30)	<.01	422	−18.44 (0.41)	<.01
Lithium		N = 87			N = 49
Week 4	74	−11.16 (0.98)	NS	41	−10.46 (1.31)	NS
Week 8	66	−17.71 (1.03)	<.05	34	−17.46 (1.43)	NS
Paroxetine		n = 74			n = 44
Week 4	59	−12.01 (1.09)	NS	38	−13.38 (1.36)	NS
Week 8	45	−16.54 (1.24)	NS	31	−15.35 (1.50)	NS
Placebo		n = 486			n = 231
Week 4	388	−11.31 (0.43)	–	198	−10.17 (0.60)	–
Week 8	304	−14.29 (0.48)	–	164	−14.57 (0.65)	–

Analyses conducted using a linear mixed model (MMRM)
ITT intent-to-treat, MADRS Montgomery–Åsberg depression rating scale, NS nonsignificant
^aProbability of comparison in change from baseline between treatment and placebo

ISSN: 1744-859X